Latest and Past News
-
CHS national committees – What do they do? What are they?
You have heard us say it, you have read about it: we are deeply grateful for the work and time and dedication of our volunteers...
-
Research projects funded in 2024
It is safe to say that research provides better quality of life and will lead, one day, inevitably to cures. This is why the Canadian...
-
Update on hemophilia gene therapy in Canada
Montreal, March 26, 2024 – Developments in gene therapy for hemophilia B have come fast and furious over the last several months. In October 2023,...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE.
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Opportunity to take part in a hemophilia B gene therapy trial
Hamilton, January 22, 2024 – McMaster University, in collaboration with CSL Behring, has announced a new gene therapy trial for etranacogene dezaparvovec (Hemgenix) in hemophilia...
-
Health Canada approves Beqvez gene therapy for hemophilia B
Ottawa – January 3, 2024 – Health Canada has authorized Beqvez (fidanacogene elaparvovec), gene therapy for the treatment of hemophilia B. Beqvez is indicated for...
-
Gene Therapy Education Program – A CHS comprehensive information program
The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages...
-
Our continuing efforts to raise awareness about women and bleeding disorders
For almost 25 years, the CHS has played a key role in raising awareness about bleeding disorders that affect women. In 2012, to ensure the...
-
Health Canada approves Hemgenix gene therapy for hemophilia B
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
-
New shared decision-making tool (SDM) by the World Federation of Hemophilia
The World Federation of Hemophilia SDM Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between people with hemophilia A or...
-
Update on gene therapy for hemophilia
Montreal, August 10, 2023 – Gene therapies for hemophilia A and B continue to move closer to becoming reality. Health Canada is currently evaluating two...
-
Pushing the limits and reaching new heights
Kilimanjaro, the roof of Africa, a dormant volcano of 5,895 meters in height is a major hiking and climbing destination that about 35,000 people attempt...
-
Patient satisfaction survey
The Canadian bleeding disorder treatment centres participed in a rigorous self-assessment of their services from November 2022 to February 2023. IT IS NOW TIME TO...